Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2020
Metadata
Show full item recordAbstract
Comment on Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. [Lancet Oncol. 2019]Citation
Adderley H, Ackermann CJ, Califano R. Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? Ann Transl Med. 2019;7(Suppl 8):S346.Journal
Annals of Translational MedicineDOI
10.21037/atm.2019.09.116PubMed ID
32016064Additional Links
https://dx.doi.org/10.21037/atm.2019.09.116Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/atm.2019.09.116